Literature DB >> 10382902

Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B.

C P Schröder1, E G de Vries, N H Mulder, P H Willemse, D T Sleijfer, G A Hospers, W T van der Graaf.   

Abstract

In a prospective randomized trial, 40 stage IV breast cancer patients undergoing intermediate high-dose chemotherapy (cyclophosphamide, 5-fluorouracil plus epirubicin or methotrexate), received either recombinant human G-CSF (rhG-CSF, group I) or ciprofloxacin and amphotericin B (CAB, group II) for prevention of febrile leucopenia (FL). In group I, seven of 18 patients developed FL (after 10/108 courses); in group II, seven of 22 patients (7/98 courses) (P = NS). Median hospitalization duration and costs were not different. RhG-CSF was 6.6 times more expensive per course than CAB. In conclusion, prophylactic CAB has similar efficacy to rhG-CSF in this setting, and is more cost-effective.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10382902     DOI： 10.1093/jac/43.5.741

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


  8 in total

Review 1.  Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.

Authors:  C J Dunn; K L Goa
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 2.  Economic evaluations of treatments for systemic fungal infections: a systematic review of the literature.

Authors:  Simon Dixon; Emma McKeen; Margaret Tabberer; Suzy Paisley
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 3.  Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.

Authors:  Marc Esser; Helmut Brunner
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

4.  A randomized multicenter phase II trial of mecapegfilgrastim single administration versus granulocyte colony-stimulating growth factor on treating chemotherapy-induced neutropenia in breast cancer patients.

Authors:  Tao Wang; Biao Wu; Xichun Hu; Jinping Liu; Tao Zhang; Funian Li; Bing Sun; Li Cai; Xinzheng Li; Zhiyue Chen; Qing Yang; Zefei Jiang
Journal:  Ann Transl Med       Date:  2019-05

Review 5.  Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.

Authors:  Nicole Skoetz; Julia Bohlius; Andreas Engert; Ina Monsef; Oliver Blank; Jörg-Janne Vehreschild
Journal:  Cochrane Database Syst Rev       Date:  2015-12-21

Review 6.  Colony-stimulating factors for chemotherapy-induced febrile neutropenia.

Authors:  Rahul Mhaskar; Otavio Augusto Camara Clark; Gary Lyman; Tobias Engel Ayer Botrel; Luciano Morganti Paladini; Benjamin Djulbegovic
Journal:  Cochrane Database Syst Rev       Date:  2014-10-30

7.  Macrophage colony-stimulating factor (M-CSF) prevents infectious death induced by chemotherapy in mice, while granulocyte-CSF does not.

Authors:  Takao Hidaka; Masaki Fujimura; Akitoshi Nakashima; Subaru Higuma; Naoko Yamagishi; Hiroshi Tsuda; Masatoshi Sakai; Shigeru Saito
Journal:  Jpn J Cancer Res       Date:  2002-04

8.  Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis.

Authors:  M Debled; N Houédé; N Madranges; C Donamaria; A Floquet; M Durand; Louis Mauriac
Journal:  Br J Cancer       Date:  2007-11-13       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.